El interés en corto de Cardiol Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Cardiol Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Informe de interés en corto

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and maintains $48 price target.

News

Price Target

Reiteration

Analyst Ratings

OMCL

Benchmark Reiterates Buy on Omnicell, Maintains $48 Price Target

<a href="https://www.nbcnews.com/news/us-news/senator-urges-doj-investigate-youth-treatment-centers-rcna174340" title="https://www.nbcnews.com/news/us-news/senator-urges-doj-investigate-youth-treatment-centers-rcna174340">https://www.nbcnews.com/news/us-news/senator-urges-doj-investigate-youth-treatment-centers-rcna174340</a>

ACHC

'Senator urges DOJ to investigate youth treatment centers after probe uncovers 'rampant abuse'' - NBC News

Citigroup analyst Ariel Rosa initiates coverage on Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) with a Neutral rating and announces Price Target of $206.

Initiation

ODFL

Citigroup Initiates Coverage On Old Dominion Freight Line with Neutral Rating, Announces Price Target of $206

WIIM

NCTY

The9 Limited shares are trading higher after the company announced its subsidiary signed a joint venture agreement with ShaoXing TongZe Network Technology, an AI and big data marketing service provider in China.

NIO Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower by 10% to $6.12 since Monday&#8217;s open amid ongoing volatility in Chinese stocks. Shares of U.S.-listed Chinese stocks are trading lower on continued weakness after Chinese planning officials reportedly fell short of investor <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41227136/chinese-stocks-plunge-as-stimulus-hopes-fade-hong-kong-posts-worst-daily-decline-si">stimulus expectations</a>. 
The Hang Seng Index plunged more than 9% Tuesday, marking its worst single-day performance since 2008, as investor sentiment was rattled by the absence of aggressive fiscal stimulus from Beijing.
The downturn has raised concerns about the future of consumer demand for electric vehicles in China, a key market for NIO and the broader EV sector.
What To Know: NIO, which has been a major player in China's growing EV industry, relies heavily on the strength of the Chinese economy and consumer spending for its sales. The company&#8217;s stock was hit hard this week as the broader market reeled from disappointment over the lack of significant economic support measures from China's National Development and Reform Commission (NDRC).
Investors had been hoping for large-scale fiscal initiatives, such as incentives for consumer spending and infrastructure projects, which could have bolstered demand for electric vehicles.
<a href="https://www.benzinga.com/markets/cannabis/24/10/41250811/exclusive-were-finally-on-the-cusp-of-something-big-verano-ceo-sees-cannabis-rescheduling-as-gam">EXCLUSIVE: &#8216;We&#8217;re Finally On The Cusp Of Something Big&#8217; — Verano CEO Sees Cannabis Rescheduling As Game-Changer</a>
Instead, the NDRC announced relatively modest measures, including a 100 billion yuan ($14.1 billion) budget for future projects, far short of the sweeping stimulus many had anticipated.
This development is particularly troubling for NIO, as the electric vehicle market in China is highly sensitive to both consumer sentiment and government policies. The Chinese government has been a strong supporter of the EV sector, providing subsidies and incentives to encourage adoption. 
However, with the economic outlook now clouded by slowing growth and a lack of aggressive fiscal support, investors are increasingly concerned that consumer demand for EVs could weaken.
What Else: NIO, which has positioned itself as a premium EV maker, is particularly vulnerable to any downturn in consumer confidence. The company&#8217;s growth strategy relies not only on increasing sales of its electric SUVs and sedans but also on expanding its ecosystem of services, including battery swapping stations and premium user experiences. 
If China's economic recovery falters, consumers may pull back on discretionary spending, including on big-ticket items like electric vehicles, potentially impacting NIO's sales.
The broader selloff in Chinese tech stocks, which included other EV makers like XPeng and Li Auto, added to the downward pressure on NIO's shares. These stocks, like NIO, are popular with foreign investors, who are quick to react to shifts in market sentiment. 
The lack of immediate fiscal stimulus from Beijing has raised fears that China's economy may face a slower recovery, which could dampen the outlook for the EV market in the near term.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41245886/disney-world-closes-early-as-hurricane-milton-approaches-florida-parks-brace-for-impact">Disney World Closes Early As Hurricane Milton Approaches Florida: Parks Brace For Impact</a>
<h2 class="wp-block-heading">How To Buy NIO Stock</h2>
By now you're likely curious about how to participate in the market for NIO &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of NIO, which is trading at $6.08 as of publishing time, $100 would buy you 16.45 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NIO has a 52-week high of $9.57 and a 52-week low of $3.61.

Why NIO Stock Is Down 10% This Week

Investors with a lot of money to spend have taken a bullish stance on Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TSLA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 160 uncommon options trades for Tesla.
This isn't normal.
The overall sentiment of these big-money traders is split between 51% bullish and 40%, bearish.
Out of all of the special options we uncovered, 60 are puts, for a total amount of $4,728,210, and 100 are calls, for a total amount of $6,025,264.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $540.0 for Tesla, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Tesla's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Tesla's whale trades within a strike price range from $5.0 to $540.0 in the last 30 days. 
<h3>Tesla Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728483444_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$5.75</td>
<td>$5.7</td>
<td>$5.7</td>
<td>$240.00</td>
<td>$305.5K</td>
<td>15.7K</td>
<td>15.6K</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$5.95</td>
<td>$240.00</td>
<td>$239.5K</td>
<td>15.7K</td>
<td>14.0K</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$241.85</td>
<td>$238.0</td>
<td>$241.63</td>
<td>$5.00</td>
<td>$193.3K</td>
<td>675</td>
<td>163</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$240.9</td>
<td>$237.0</td>
<td>$240.67</td>
<td>$5.00</td>
<td>$192.5K</td>
<td>675</td>
<td>87</td>
</tr>
<tr>
<td>TSLA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$2.55</td>
<td>$2.52</td>
<td>$2.55</td>
<td>$260.00</td>
<td>$123.5K</td>
<td>39.7K</td>
<td>10.8K</td>
</tr>
</tbody>
</table>

<h3>About Tesla</h3>
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi-truck. Tesla also plans to begin selling more affordable vehicles, and a sports car. Global deliveries in 2023 were a little over 1.8 million vehicles. The company also sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
Following our analysis of the options activities associated with Tesla, we pivot to a closer look at the company's own performance.
<h3>Tesla's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 12,887,827, the TSLA's price is down by -0.88%, now at $242.34. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 14 days.</li>
</ul>
<h3>What The Experts Say On Tesla</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $239.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $245. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Tesla, which currently sits at a price target of $236. 
&#x2A; An analyst from Truist Securities downgraded its action to Hold with a price target of $236. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $245. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Tesla with a target price of $236. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tesla, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

TSLA

Tesla Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bullish stance on Booking Holdings.
Looking at options history for Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 18% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $145,036 and 6, calls, for a total amount of $363,448.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $3900.0 to $4630.0 for Booking Holdings over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Booking Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Booking Holdings's whale trades within a strike price range from $3900.0 to $4630.0 in the last 30 days. 
<h3>Booking Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728483439_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$172.8</td>
<td>$164.2</td>
<td>$164.2</td>
<td>$4115.00</td>
<td>$164.2K</td>
<td style="text-align: right;">15</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/22/24</td>
<td>$213.0</td>
<td>$195.1</td>
<td>$204.1</td>
<td>$4240.00</td>
<td>$61.2K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$453.0</td>
<td>$436.5</td>
<td>$446.1</td>
<td>$4300.00</td>
<td>$44.6K</td>
<td style="text-align: right;">18</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>BKNG</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$409.7</td>
<td>$393.9</td>
<td>$398.74</td>
<td>$4630.00</td>
<td>$39.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$374.1</td>
<td>$362.0</td>
<td>$367.0</td>
<td>$3900.00</td>
<td>$36.7K</td>
<td style="text-align: right;">50</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>

<h3>About Booking Holdings</h3>
Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Following our analysis of the options activities associated with Booking Holdings, we pivot to a closer look at the company's own performance.
<h3>Current Position of Booking Holdings</h3>
<ul>
<li>Currently trading with a volume of 11,087, the BKNG's price is up by 0.58%, now at $4257.69. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 21 days.</li>
</ul>
<h3>What The Experts Say On Booking Holdings</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $3888.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Booking Holdings, targeting a price of $4500. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $3590. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $3590. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on Booking Holdings with a target price of $4173. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $3590. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Booking Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

BKNG

Booking Holdings Unusual Options Activity For October 09

Investors with a lot of money to spend have taken a bearish stance on Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Salesforce.
This isn't normal.
The overall sentiment of these big-money traders is split between 25% bullish and 50%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $61,226, and 6 are calls, for a total amount of $306,449.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $250.0 to $340.0 for Salesforce over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Salesforce's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Salesforce's whale activity within a strike price range from $250.0 to $340.0 in the last 30 days. 
<h3>Salesforce 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728483435_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$20.2</td>
<td>$19.3</td>
<td>$20.05</td>
<td>$340.00</td>
<td>$98.2K</td>
<td>159</td>
<td style="text-align: right;">77</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$12.7</td>
<td>$12.15</td>
<td>$12.39</td>
<td>$280.00</td>
<td>$61.9K</td>
<td>4.2K</td>
<td style="text-align: right;">52</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/01/24</td>
<td>$43.45</td>
<td>$41.55</td>
<td>$42.1</td>
<td>$250.00</td>
<td>$42.1K</td>
<td>39</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$20.25</td>
<td>$19.35</td>
<td>$20.05</td>
<td>$340.00</td>
<td>$40.1K</td>
<td>159</td>
<td style="text-align: right;">117</td>
</tr>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$6.35</td>
<td>$5.95</td>
<td>$6.35</td>
<td>$285.00</td>
<td>$34.9K</td>
<td>122</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>

<h3>About Salesforce</h3>
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
<h3>Where Is Salesforce Standing Right Now?</h3>
<ul>
<li>With a volume of 514,628, the price of CRM is down -1.09% at $288.39. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 49 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Salesforce with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

A Closer Look at Salesforce's Options Market Dynamics

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are in the spotlight Wednesday ahead of the EV company's long-awaited robotaxi event this week. Tesla also saw record <a href="https://www.benzinga.com/news/24/09/40768611/elon-musk-shoots-down-reports-of-teslas-china-woes-amid-intense-competition-says-giga-shanghai-is-ru">China shipments last month</a>.
What Happened: According to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-10-09/tesla-sees-record-quarterly-china-shipments-on-ev-subsidy-boost?sref=TBDibEcD">report</a> citing preliminary data from China's Passenger Car Association, Tesla shipped approximately 88,321 Model 3 and Model Y vehicles from its Shanghai factory in September, up 19% year-over-year. 
The record China shipments mark the third straight month of climbing vehicle deliveries in China. The reported total brings the company&#8217;s third-quarter China shipments up to 249,135, above the prior peak of 248,686 vehicles shipped from its Shanghai factory in the fourth quarter of 2023. 
Although Tesla appears to be seeing strength in China, the company&#8217;s <a href="https://www.benzinga.com/news/24/10/41141444/tesla-stock-plunges-3-despite-q3-deliveries-exceeding-consensus-and-growing-year-over-year">third-quarter delivery total of 462,890</a> came up short of some analyst expectations, per Bloomberg. 
Tesla has reportedly benefitted from a 20,000 yuan ($2,830) government&nbsp;subsidy in China, making it easier for consumers to trade in old vehicles for new EVs. The subsidy is expected to remain in place into October.
Check This Out: <a href="https://www.benzinga.com/markets/equities/24/10/41244101/teslas-party-could-be-crashed-by-baidu-as-chinese-rival-considers-global-robotaxi-expansion">Tesla&#8217;s Party Could Be Crashed By Baidu As Chinese Rival Considers Global Robotaxi Expansion</a>
Investors and analysts have shifted their attention to Tesla&#8217;s highly anticipated&nbsp;robotaxi event, "We, Robot," scheduled to kick off Thursday night. Many expect Tesla to unveil what will drive the next growth phase for the company. 
Wedbush&nbsp;analyst&nbsp;Dan Ives&nbsp;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41106025/tesla-analyst-sets-the-stage-for-game-changing-robotaxi-event-anticipates-seminal-a">set the stage for the event</a> in a note to clients last week. The analyst anticipates several "game changing" updates and details surrounding Tesla's robotaxi platform, rumored to be called the&nbsp;"Cybercab."
"We believe Robotaxi Day will be seminal and historical day for Musk and Tesla and marks a new chapter of growth around autonomous, FSD, and AI future at Tesla," Ives said
Ark Invest&nbsp;analyst&nbsp;Tasha Keeney said in a blog post this week that she expects Tesla's autonomous platform to account for approximately 90% of Tesla&#8217;s valuation in five years. 
&#8220;Like Waymo, Tesla is likely to launch its robotaxi service city by city; but unlike Waymo, it should be able to scale much faster, because it will not rely on HD maps or geofencing,&#8221; Keeney said.
Tesla&#8217;s robotaxi event this week will be followed by <a href="https://www.benzinga.com/calendars/earnings">third-quarter earnings</a> later this month. Tesla is scheduled to report quarterly results after the market close on Oct. 23. Analysts expect the EV maker to report earnings of 57 cents per share and revenue of $25.238 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
TSLA Price Action: <a href="http://benzinga.com/quote/tsla">Tesla shares</a> were down 0.42% at $243.48 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41247281/teslas-robotaxi-platform-could-account-for-90-of-ev-giants-enterprise-value-over-th">Tesla&#8217;s Robotaxi Platform Could Account For 90% Of EV Giant&#8217;s Enterprise Value Over The Next 5 Years, Says Ark Invest Analyst</a></li>
</ul>
Photo: courtesy of Tesla.

Global

Movers

What's Going On With Tesla Stock Wednesday?

<a href="https://www.benzinga.com/events/cannabis-conference/livestream/">https://www.benzinga.com/events/cannabis-conference/livestream/</a>
&nbsp;

Cannabis

Events

Exclusives

CRLBF

MSOS

Live Now At Benzinga's Cannabis Capital Conference: Charlie Bachtell Keynote

Inflation has everyone talking, and the soaring housing cost is at the center of the conversation. It's not just a hot headline topic – <a href="https://www.benzinga.com/startups/24/10/41197078/hes-just-not-very-serious-says-kamala-harris-you-dont-just-throw-around-the-idea-of-tariffs-across-t">Kamala Harris</a> and Donald Trump have made it a major point in their 2024 presidential campaigns. Both Harris and Trump say they've got solutions, but not all ideas will hit the mark.
Harris, for example, is proposing direct help for first-time homebuyers. She wants to provide up to $25,000 in down-payment assistance, plus a $10,000 tax credit. However, there's a catch: whenever you throw money into a competitive housing market, it can drive prices up even further.&nbsp;
Don't Miss:
<ul>
<li>Beating the market through ethical real estate investing' — t<a href="https://www.benzinga.com/money/invest-with-roots">his platform aims to give tenants equity in the homes they live in while scoring 17.17% average annual returns for investors – here&#8217;s how to join with just $100</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
Experts who spoke to ABC cited past programs in which the government helped push prices higher, benefiting sellers more than buyers.
Carla Krolage, an economist, highlighted a similar situation in Bavaria, Germany. A subsidy program there led to a price jump of about 10,000 euros per home. Harris's plan could have a similar effect, with home prices climbing rather than falling. Ed Pinto from the American Enterprise Institute voiced concerns that the $25,000 grant might raise home costs across the board, defeating the purpose of the assistance.
See Also: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
Still, Harris's focus on affordability and supply hasn't been seen in decades. David Dworkin of the National Housing Conference noted that her campaign's comprehensive housing plan is a sign that the crisis is being taken seriously. He also dismissed fears of skyrocketing prices, saying that combining down-payment assistance with investments in housing supply could avoid inflation.
Harris is also pushing for tax incentives for builders, which she believes will add three million new homes to the market. These incentives target starter homes and affordable rental units.&nbsp;
Trending: Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a>
Such measures aren't entirely new; there's already a tax credit for developers under the Low-Income Housing Tax Credit (LIHTC), which has existed since 1986. While helpful, past reports show the program has become less efficient over time, producing fewer homes at a greater cost.
Trump, on the other hand, has a different approach. He wants to ban undocumented immigrants from getting mortgages, a move he says would cool the housing market. While<a href="https://www.benzinga.com/real-estate/24/09/40939943/elon-musk-mark-zuckerberg-and-jay-z-take-out-mortgages-despite-their-billion-dollar-fortunes-heres-w"> home loans</a> for undocumented immigrants are rare, Trump's proposal could also affect construction workers.&nbsp;
Trending: These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>
With nearly 20% of U.S. construction labor made up of immigrants, many of whom are undocumented, restricting this workforce could lead to labor shortages and higher building costs. That would make meeting the country's growing housing demand even harder.
Another Trump plan involves loosening zoning laws, which he blames for slowing down construction and inflating costs. He argues that environmental regulations and complex permitting processes are holding builders back.
&nbsp;It's true that some cities, like Minneapolis, have already made moves to end single-family zoning to create more housing, but local resistance remains a challenge. Homeowners often push back on plans for denser, more affordable developments, wanting to protect their property values.
Read Next:
<ul>
<li>Can you guess which type of investments Morgan Stanley says will reach $2.7 trillion by 2027?<a href="https://www.benzinga.com/money/percent"> It even offers up to 20% APY potential to accredited investors up to $300 back in bonus for new users.</a></li>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
</ul>

Real Estate

Trump and Harris Reveal Their Game Plans to Tackle Skyrocketing Housing Prices – Here's What Has Worked Before and What Might Now

Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) will release earnings results for its third quarter, after the <a href="https://www.benzinga.com/quote/DPZ/earnings">closing bell on Thursday, Oct. 10</a>.
Analysts expect the Ann Arbor, Michigan-based company to report quarterly earnings at $3.65 per share, down from $4.18 per share in the year-ago period. Domino&#8217;s projects to report revenue of $1.1 billion for the quarter, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 18, the company reported second-quarter FY24 sales growth of 7.1% year-on-year to $1.097 billion, missing the analyst consensus estimate of $1.103 billion.
Domino&#8217;s shares gained 0.3% to close at $411.15 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/TJX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5df37c17bffdfc0001d738fc/brian-mullan">Piper Sandler analyst Brian Mullan</a> maintained a Neutral rating and cut the price target from $436 to $429 on Oct. 7. This analyst has an accuracy rate of 78%.</li>
<li>Wedbush analyst Nick Setyan maintained an Outperform rating and slashed the price target from $510 to $470 on Oct. 4. This analyst has an accuracy rate of 71%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/591c7409290fa70001b157ca/gregory-francfort">Guggenheim analyst Gregory Francfort</a> maintained a Neutral rating and decreased the price target from $485 to $460 on Sept. 26. This analyst has an accuracy rate of 71%.</li>
<li>JP Morgan analyst John Ivankoe maintained a Neutral rating and boosted the price target from $450 to $470 on Sept. 16. This analyst has an accuracy rate of 72%.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58b05502b85e93000174c0ed/andrew-charles">TD Cowen analyst Andrew Charles</a> maintained a Buy rating and slashed the price target from $520 to $475 on Sept. 16. This analyst has an accuracy rate of 73%.</li>
</ul>
Considering buying DPZ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09032203/image-54-1024x495.png" alt="" class="wp-image-587028" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09032203/image-54-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09032203/image-54-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09032203/image-54-768x371.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09032203/image-54.png 1386w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a></li>
</ul>

Earnings

Trading Ideas

Domino's Earnings Are Imminent; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Loop Capital analyst Laura Champine upgraded the rating for The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) from Hold to Buy and raised the price target from $360 to $460. Home Depot shares closed at $414.18 on Tuesday. <a href="https://www.benzinga.com/quote/HD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Devin Ryan upgraded Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) from Market Perform to Market Outperform and announced a $146 price target. Raymond James Finl shares closed at $124.90 on Tuesday. <a href="https://www.benzinga.com/quote/RJF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Sheila Kahyaoglu upgraded the rating for Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) from Underperform to Hold and raised the price target from $24 to $32. Southwest shares settled at $30.67 on Tuesday. <a href="https://www.benzinga.com/quote/LUV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst James Faucette upgraded Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) from Underweight to Equal-Weight and raised the price target from $20 to $37. Affirm shares closed at $41.15 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst James Hardiman upgraded the rating for Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) from Neutral to Buy and boosted the price target from $20 to $30. Norwegian Cruise shares closed at $20.80 on Tuesday. <a href="https://www.benzinga.com/quote/NCLH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying HD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="523" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09094407/image-64-1024x523.png" alt="" class="wp-image-587760" style="width:656px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09094407/image-64-1024x523.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09094407/image-64-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09094407/image-64-768x392.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09094407/image-64.png 1305w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a></li>
</ul>

Upgrades

AFRM

NCLH

This Home Depot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

U.S. stocks traded mixed this morning, with the Dow Jones index gaining more than 100 points on Wednesday.
Following the market opening Wednesday, the Dow traded up 0.35% to 42,226.68 while the NASDAQ fell 0.20% to 18,146.90. The S&amp;P 500 also rose, gaining, 0.03% to 5,752.58.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/10/41249094/how-to-earn-500-a-month-from-jpmorgan-stock-ahead-of-q3-earnings">How To Earn $500 A Month From JPMorgan Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Financials shares jumped by 0.5% on Wednesday.
In trading on Wednesday, communication services shares fell by 0.9%.
Top Headline
Helen Of Troy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HELE#NASDAQ">HELE</a>) reported better-than-expected second-quarter results, reaffirming its FY25 sales and EPS outlook.
The company reported a second-quarter sales decline of 3.5% year-over-year to $474.221 million, beating the analyst consensus of $458.237 million. Adjusted EPS declined 34.1% YoY to $1.21, beating the consensus estimate of $1.04.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Momentus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares shot up 91% to $0.7966 after the company announced a NASA contract to provide launch services for future agency missions.</li>
<li>Shares of Banzai International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) got a boost, surging 80% to $4.9699 after the company announced strategic business initiatives to improve net income.</li>
<li>Inhibikase Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) shares were also up, gaining 38% to $1.65 after the company announced the pricing of an approximately $110 million private placement financing.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sacks Parente Golf, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPGC#NASDAQ">SPGC</a>) shares dropped 46% to $1.96 after gaining 35% after the company announced a $732K public offering of 366,000 shares of common stock for general corporate and working capital needs.</li>
<li>Shares of BAIYU Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYU#NASDAQ">BYU</a>) were down 43% to $0.5712.</li>
<li>Alternus Clean Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) was down, falling 37% to $0.0903 after the company announced a 1-for-25 reverse stock split as part of its Nasdaq compliance plan.</li>
</ul>
Commodities In commodity news, oil traded down 2.2% to $71.97 while gold traded down 0.3% at $2,627.90.
Silver traded up 0.2% to $30.645 on Wednesday, while copper fell 1.6% to $4.3870.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.3%, Germany's DAX gained 0.5% and France's CAC 40 rose 0.3%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 rose 0.4%.
Germany&#8217;s trade surplus increased to EUR 22.5 billion in August versus a revised EUR 16.9 billion in the prior month, topping market estimates of EUR 18.4 billion.
Asia Pacific Markets
Asian markets closed mostly lower on Wednesday, with Japan's Nikkei 225 gaining 0.87%, Hong Kong's Hang Seng Index dipping 1.38%, China's Shanghai Composite Index falling 6.62% and India's BSE Sensex dipping 0.21%.
Japan's machine tool orders declined 6.5% year-over-year to JPY 125,297 million in September compared to a 3.5% decline in the prior month, while the Reuters Tankan sentiment index for manufacturers climbed to +7 in October versus +4 in September. The Reserve Bank of India maintained its benchmark policy repo rate at 6.5% during October meeting.
Economics
U.S. mortgage applications declined by 5.1% from the previous week during the first week of October, compared to a 1.3% drop in the prior week.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41248833/jim-cramer-says-hes-buying-some-target-but-dismisses-soundhound-ai-as-meme-stock"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41248833/jim-cramer-says-hes-buying-some-target-but-dismisses-soundhound-ai-as-meme-stock">Jim Cramer Says He&#8217;s Buying &#8216;Some Target,&#8217; But Dismisses SoundHound AI As &#8216;Meme Stock</a><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41248833/jim-cramer-says-hes-buying-some-target-but-dismisses-soundhound-ai-as-meme-stock">&#8216;</a></li>
</ul>
<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41248833/jim-cramer-says-hes-buying-some-target-but-dismisses-soundhound-ai-as-meme-stock">&nbsp;</a>

Equities

Eurozone

Commodities

ALCE

BNZI

HELE

MNTS

SPGC

Dow Jumps Over 100 Points; Helen Of Troy Posts Upbeat Q2 Results

Rumors

IPOs

KinderCare Learning Companies IPO Indicating $25-$26/Share; IPO Priced At $24/Share On 24M Shares

<a href="https://www.beyondmeat.com/en-US/whats-new/mcdonald-s-france-launches-veggie-mcplant-nuggets" title="https://www.beyondmeat.com/en-US/whats-new/mcdonald-s-france-launches-veggie-mcplant-nuggets">https://www.beyondmeat.com/en-US/whats-new/mcdonald-s-france-launches-veggie-mcplant-nuggets</a>

BYND

Reported October 8: 'MCDONALD'S FRANCE LAUNCHES VEGGIE MCPLANT NUGGETS' - Beyond Meat

On Wednesday, Viking Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) released data from the Phase&nbsp;1b trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRβ), in patients with X-linked <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41246671/viking-therapeutics-announces-results-from-phase-1b-clinical-trial-of-vk0214-in-patients-with-x-al" rel="noreferrer noopener">adrenoleukodystrophy (X-ALD)</a>.&nbsp;
X-linked adrenoleukodystrophy is&nbsp;a genetic disorder that mainly affects the nervous system and the adrenal glands, which are located on top of each kidney.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39966690/viking-therapeutics-stock-surges-as-company-advances-weight-loss-drug-to-late-stage-trial-what-inves" rel="noreferrer noopener">Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know</a>.
Results showed VK0214 to be safe and well-tolerated following once-daily dosing over the 28-day study period.
In addition, plasma levels of very long-chain fatty acids (VLCFAs) and other lipids were significantly reduced compared to placebo.
VLCFAs are considered biomarkers of disease in patients with X-ALD.&nbsp; Treatment with VK0214 resulted in significant reductions in mean VLCFA levels at both doses evaluated, 20 mg/day and 40 mg/day, compared to placebo.
Cohorts receiving VK0214 demonstrated reductions in mean plasma levels of the 26 carbon lysophosphatidyl choline (C26:0-LPC) derivative, a key diagnostic marker.&nbsp;
A 14.8% reduction was observed in the 40 mg cohort (p=0.0105) and a reduction of 8.4% in the 20 mg cohort (p=0.0427). In addition to VLCFA changes, subjects who received VK0214 demonstrated reductions in other plasma lipids.
Mean reductions relative to baseline and placebo were observed for low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and lipoprotein (a) [Lp(a)] following 28 days of treatment.&nbsp;
Treatment-emergent adverse events were reported as mild to moderate. Gastrointestinal adverse events were slightly higher among placebo subjects (33%) compared with VK0214-treated subjects (11%).
William Blair highlights that the positive progress of VK0214 provides investors with additional opportunities beyond Viking's existing programs, including the subcutaneous and oral formulations of VK2735 for obesity, VK2809 for metabolic-dysfunction-associated steatohepatitis (MASH), and its preclinical amylin program, which is expected to enter clinical trials next year.
Since the analyst believes most investors have yet to factor in the potential revenue from VK0214, its continued successful development could offer an upside to current projections. Moreover, the focus on treating an orphan disease broadens Viking's potential revenue streams by expanding from the larger obesity and MASH markets into the rare disease space.
Price Action: VKTX stock is down 2.67% at $64.90 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41249524/honda-recalls-1-7m-vehicles-over-steering-gearbox-defect" target="_blank" rel="noreferrer noopener">Honda Recalls 1.7M Vehicles Over Steering Gearbox Defect</a>.</li>
</ul>

Analyst Color

Biotech

Health Care

General

VKTX

Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams

Stephens &amp; Co. analyst Scott Fidel reiterates Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and maintains $250 price target.

Stephens & Co. Reiterates Equal-Weight on Humana, Maintains $250 Price Target

Oppenheimer analyst Leland Gershell maintains Immunovant (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>) with a Outperform and raises the price target from $47 to $53.

IMVT

Oppenheimer Maintains Outperform on Immunovant, Raises Price Target to $53

Wells Fargo analyst Michael Brown upgrades LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) from Equal-Weight to Overweight and raises the price target from $235 to $285.

LPLA

Wells Fargo Upgrades LPL Finl Hldgs to Overweight, Raises Price Target to $285

Cardiol Therapeutics (CRDL) has received a new Buy rating, initiated by Roth MKM analyst, Jason Wittes. Jason Wittes has given his Buy rating due t...

Buy Rating on Cardiol Therapeutics: Promising CardioRx Pipeline and Positive Clinical Trials

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. successfully held its 2024 Annual General and Special Meeting whe...

Cardiol Therapeutics Shareholders Approve Resolutions

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. has received consent from Borden Ladner Gervais LLP for the use o...

Cardiol Therapeutics Gains Key Legal Consent

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc. reported a decrease in total assets from CAD 36.7 million as of D...

Cardiol Therapeutics Inc.: Financial Update

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Cardiol Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/crdl-stock-quote/">CRDL</a>) just reported results for the second quarter of 2024.<ul><li>Cardiol Therapeutics reported earnings per share of -7.3 cents. This was above the analyst estimate for EPS of -9 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/crdl-stock-earnings-cardiol-therapeutics-for-q2-of-2024/">CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024

Cardiol Therapeutics: First-Mover In CBD-Based Treatment For Heart Disease

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has successfully completed the MAvERIC Phase II study for recurrent pe...

Cardiol Therapeutics Advances Heart Disease Treatment

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics has successfully enrolled 100 patients in its Phase II ARCHER trial, t...

Cardiol Therapeutics' Landmark Enrollment for Heart Drug Trial

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics Inc., a clinical-stage company specializing in heart disease treatment...

Cardiol Therapeutics Announces Public Share Offering

Cardiol Therapeutics (TSE:CRDL) has released an update. Cardiol Therapeutics, a clinical-stage life sciences company, has announced the pricing of ...

Cardiol Therapeutics Sets Common Share Offering Price

CRDL

Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development

Press Releases

Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis

Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients

Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT

Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

"Cardiol Therapeutics (NASDAQ: CRDL) Myocarditis Breakthrough Featured on Fox Business: CardiolRx™ Poised for Medical Impact more stocks inside…"

Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares

Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares

KAVL

PEGY

PRSO

SMFL

TNON

TSX:CRDL

UMAC

Roth MKM

HC Wainwright & Co.

Canaccord Genuity

Cantor Fitzgerald

Cardiol Therapeutics shares are trading lower after the company announced a $13.5 million public offering of 8,437,500 common shares priced at $1.60 per unit.

Comments

Cardiol Therapeutics

Interés en corto

Cardiol Therapeutics (NASDAQ:CRDL) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL